The Levonorgestrel-releasing intrauterine device: A wider role than contraception

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 37, Issue 2, 1997, Pages 195-201

  Coleman, Matthew ^a   McCowan, Lesley ^a   Farquhar, Cynthia ^a  

^a NATIONAL WOMEN S HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; LEVONORGESTREL;

AUSTRALIA; BLEEDING; BREAST FEEDING; CLIMACTERIUM; CONTRACEPTION; DRUG RELEASE; ECTOPIC PREGNANCY; FEMALE; HUMAN; HYSTERECTOMY; INTRADERMAL DRUG ADMINISTRATION; INTRAUTERINE CONTRACEPTIVE DEVICE; INTRAUTERINE DRUG ADMINISTRATION; MENSTRUATION; NEW ZEALAND; ORAL DRUG ADMINISTRATION; PAIN; PELVIC INFLAMMATORY DISEASE; PRIORITY JOURNAL; PUERPERIUM; REVIEW; SYMPTOM; UTERUS MYOMA;

EID: 0030970629     PISSN: 00048666     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1479-828X.1997.tb02253.x     Document Type: Review

References (68)

1. Anonymous. Mechanism of action, safety and efficacy of intrauterine devices. Report of a WHO Scientific Group. WHO Technical Report Series. 1987; 753
2. Sivin I. Dose and age-dependent ectopic pregnancy risks with intrauterine contraception. Obstet Gynecol 1991; 78: 291-298.
3. Larsen S, Hansen MK, Jacobsen JC, Ladehoff P, Sorensen T, Westergaard JG. Comparison between two IUDs: Progestasert and Cu T 200. Contracept Delivery Syst 1981; 2: 281-286.
4. Rybo G. The IUD and endometrial bleeding. J Reprod Med 1978; 20: 175-182.
5. Luukkainen T, Haukkamaa M. Lahteenmaki P, Toivonen J. Progress in birth control vaccines. The levonorgestrel releasing intrauterine device. Edited by Talwar GP, New York. Springer-Verlag, 1988, p. 37-48.
6. Luukkainen T, Lahteenmaki PL, Toivonen J. Levonorgestrel releasing intrauterine device. Ann Med 1990; 22: 85-90.
7. Silverberg SG, Haukkamaa M, Arko H, Nilsson CG, Luukkainen T. Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices. Int J Gynecol Pathol 1986; 5: 235-241.
8. Luukkainen T, Allonen H, Haukkamaa M, Lahteenmaki P, Nilsson CG, Toivonen J. Five years' experience with levonorgestrel-releasing IUDs. Contraception 1986; 33: 139-148
9. Xiao B, Zeng T, Wu S, Sun H, Xiao N. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use. Contraception 1995; 51: 359-365.
10. Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices; a multicenter study. International Committee for Contraception Research (ICCR). Fertil Steril 1994; 61: 70-77.
11. Diaz J, Faundes A. Diaz M, Marchi N Evaluation of the clinical performance of a levonorgestrel-releasing IUD, up to seven years of use, in Campinas, Brazil. Contraception 1993; 47: 169-175.
12. Sivin I, Stern J, Coutinho E et al. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20. Contraception 1991; 44: 473-480.
13. Videla-Rivero L, Etchepareborda JJ, Kesseru E. Early chorionic activity in women bearing inert IUD, copper IUD and levonorgestrel-releasing IUD. Contraception 1987; 36: 217-226.
14. Ortiz ME, Croxatto H. Mode of action of IUDs. Contraception 1987; 36: 37-53.
15. Jonsson B, Landgren BM, Eneroth P. Effects of various IUDs on the composition of cervical mucus. Contraception 1991; 43: 447-458.
16. Barbosa I, Olsson SE, Odlind V, Goncalves T, Coutinho E. Ovarian function after seven years' use of a levonorgestrel IUD. Adv Contracept 1995; 11: 85-95.
17. Xiao B, Liying Z, Xuling Z, Mengchun J. Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device. Contraception 1990; 41: 353-362.
18. Barbosa I, Bakos O, Olsson SE, Odlind V, Johansson ED. Ovarian function during use of a levonorgestrel-releasing IUD. Contraception 1990; 42 51-66.
19. Bounds W, Robinson G. Clinical experience with a levonorgestrel releasing intrauterine contraceptive device (LNG-IUD) as a contraceptive and in the treatment of menorrhagia. Br J Fam Plann. 1993; 19: 193-194.
20. Guillebaud J. Contraception your questions answered. 2nd Edition, Edinburgh, Churchill Livingstone, 1993. Introduction: The population explosion and the importance of fertility control. p.1-12.
21. Indian Council of Medical Research and Task Force on IUDs. Randomised clinical trials with intrauterine devices (levonorgestrel intrauterine device LNG) CuT380Ag. Cu220C. CuT200B A 36 month study. Contraception 1987; 39: 37-52.
22. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994; 49: 56-72.
23. Wang SL, Wu SC, Xin XM, Chen JH, Gao J. Three years' experience with levonorgestrel-releasing intrauterine device and Norplant-2 implants: a randomized comparative study. Adv Contracept 1992; 8: 105-114.
24. Faundes A, Alvarez F, Diaz JA. Latin American experience with levonorgestrel IUD. Ann Med 1993; 25: 149-153.
25. Heikkila M, Luukkainen T. Duration of breast-feeding and development of children after insertion of a levonorgestrel-releasing intrauterine contraceptive device. Contraception 1982; 25: 279-292.
26. Heikkila M, Haukkamaa M, Luukkainen T. Levonorgestrel in milk and plasma of breast-feeding women with a levonorgestrel-releasing IUD. Contraception 1982; 25: 41-49.
27. Andersson K, Batar I, Ryho G. Return to fertility after removal of a levonorgestrel-releasing intrauterine device and Nova-T. Contraception 1992; 46: 575-584.
28. Sivin I, Stern J. Diaz S et al. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices. Contraception 1992; 166: 1208-1213.
29. Belhadj H, Sivin I, Diaz S et al. Recovery of fertility after use of the levonorgestrel 20 mcg/d or Copper T 380 Ag intrauterine device. Contraception 1986; 34: 261-267.
30. Nilsson CG. Fertility after discontinuation of levonorgestrel releasing intrauterine device. Contraception 1982; 25. 273-278.
31. Westrom L. Genital tract infection in women. Long-term consequences of pelvic inflammatory disease. Edinburgh. Churchill Livingstone. Edited by Hare MJ. 1988. p. 350-367.
32. Buchan H. Vessey M. Epidemiology and trends in hospital discharges for pelvic inflammatory disease in England 1975-1985. Br J Obstet Gynaecol 1989; 96: 1219-1223.
33. Westrom L. Effect of acute pelvic inflammatory disease on fertility. Am J Obstet Gynecol 1975; 121: 707-713.
34. Westrom L, Bengtsson LP, Mardh PA. The risk of pelvic inflammatory disease in women using intrauterine contraceptive devices as compared to non users Lancet 1976; 2: 221-224.
35. Buchen H, Villard-Mackintosh L, Vessey M, Yeates D. McPherson K Epidemiology of pelvic inflammatory disease in parous women with special reference to intrauterine device use. Br J Obstet Gynaecol 1990, 97: 780-788.
36. Farley TMM, Rosenberg M, Rowe PJ, Chien J-H, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992; 339. 785-788.
37. Toivonen J, Luukkainen T, Allonen H. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years' comparative experience of levonorgestrel- and copper-releasing intrauterine devices [see comments]. Obstet Gynecol 1991; 77: 261-264.
38. Shaw STE. Quantitative menstrual and intermenstrual blood loss in women using Lippes Loop and copper T intrauterine devices. Contraception 1980; 21: 343-352.
39. Cole LP, Potts DM, Aranda C et al. An evaluation of the Tcu380 Ag and the multiload Cu375. Fertil Steril 1985; 43: 214-217.
40. Bergkvist A, Rybo G. Treatment of menorrhagia with intauterine release of progesterone. Br J Obstet Gynaecol 1983; 90: 255-258
41. Andersson K. Levonorgestrel releasing intrauterine devices in the treatment of menorrhagia. Br J Obstet Gynaecol 1990; 97: 690-94.
42. Milsom I, Andersson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol 1991; 164: 879-883.
43. Faundes A, Alvarez F, Brache V, Tejada AS. The role of the levonorgestrel intrauterine device in the prevention and treatment of iron deficiency anemia during fertility regulation. Int J Gynaecol Obstet 1988; 26: 429-443.
44. Shaw ST Intrauterine contraception: recent advances and future prospects Edited by Zatuchni, G.I. Philadelphia Harper and Row. 1985. Endometrial histopathology and ultrastructural changes with IUD use. p. 276-296.
45. Liedholm PE. No increase in the fibrinolytic activity of the human endometrium by the progesterone releasing IUD (Progestasert). Contraception 1978; 17: 531-540.
46. Singer A, Ikomi A Successful treatment of uterine fibroids using an intrauterine progesterone device. XIV FIGO Congress, Montreal, Canada, 1994. (Abstract)
47. Guidence LC, Irwin JC, Dsupin BAEA. Insulin-like growth factor (IGF). IGF binding protein (IGFBP) and IGF receptor gene expression and IGFBP synthesis in human uetrine leiomyomata. Hum Reprod 1993; 8: 1796-1806.
48. Pekonen F, Nyman T, Lahteenmaki P, Haukkamaa M, Rutanen EM. Intauterine progestin induces continous insulin like growth factor-binding protein-1 production in the human endometrium, J Clin Endocrinol Metabol 1992; 75: 660-664.
49. Nilsson CG, Luukkainen T, Diaz J, Allonen H, Clinical performance of a new LNG releasing IUD. A randomised comparison with a Nova T copper device. Contraception 1982; 25: 345-356.
50. Persson I, Adami HO, Bergkvist LE. Risk of endometrial cancer after treatment with oestrogens alone and in conjunction with progestogens. Results of a prospective study. B M J- 1989; 298: 147-151.
51. Ferguson K, Hoegh C, Johnson S. Estrogen replacement therapy. A survey of women's knowledge and attitudes. Arch Int Med 1989; 149: 133-136.
52. Hahn RG. Compliance considerations with estrogen replacment: Withdrawl bleeding and other factors. Am J Obstet Gynecol 1989; 161: 1854-1858.
53. Hammarbach S, Backstrom T, Holst J, von-Schoultz B, Lyrenas S. Cyclical mood changes as in the premenstrual tension syndrome during sequential estrogen-progestagen postmenopausal replacement therapy. Acta Obstet Gynecol Scand 1985; 64: 393-397.
54. Andersson K, Mattsson L., Rybo G, Stadberg E. Intrauterine release of levonorgestrel-A new way of adding progestogen in hormone replacement therapy. Obstet Gynecol 1992; 79: 963-967.
55. Suhonen SP, Holmstrom T, Allonen HO, Lahteenmaki P. Intrauterine and subdermal progestin administration in postmenopausal hormone replacement therapy. Fertil Steril 1995; 63: 336-342.
56. Suhonen SP, Allonen HO, Lahteenmaki P. Sustained-release estradiol implants and a levonorgestrel-releasing intrauterine device in hormone replacement therapy. Am J Obstet Gynecol 1995; 172: 562-567.
57. Raudadkoski TH, Tomas EI, Kauppila AJ, Laatikainen TJ. Serum lipids and lipoproteins in postmenopausal women receiving transdermal oestrogen in combination with a levonorgestrel-releasing intrauterine device. Maturitas 1995; 22: 47-53.
58. Nachigall LE, Nachigall RH. Nachtigall RB, Beckman EM. Estrogen replacment II: A prospective study in the relationship to carcinoma and cardiovascular and metabollic problems. Obstet Gynecol 1979; 54: 74-79.
59. Shapiro S, Kelly JP, Rosenberg LE. Risk of localised and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Engl J Med 1985; 313: 969-972.
60. Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol Oxf 1982; 17: 529-536.
61. Perino A, Quartararo P, Catinella E, Genova G, Cittadini E. Treatment of endometrial hyperplasia with levonorgestrel releasing devices. Acta Eur Fertil 1987; 18: 137-140.
62. Scarselli G, Tantini C, Colafranceschi M et al. Levo-norgestrelnova-T and precancerous lesions of the endometrium. Eur J Gynaecol Oncol 1988; IX: 284-286.
63. Tayob Y, Adams J, Jacob H et al. Ultrasound demonstration of increased frequency of functional ovarian cysts in women using progestogen-only contraception. Br J Obstet Gynaecol 1985; 92: 1003-1009.
64. Kurunmaki H. Contraception with levonorgestrel-releasing subdermal capsules. Norplant after pregnancy termination. Contraception 1983; 27: 473-482.
65. Robinson GE, Bounds W, Kubbal AAE. Functional ovarian cysts associated with the levonorgestrel-releasing intrauterine device. Br J Fam Plann 1989; 14: 131-132.
66. Nilsson CG, Lahteenmaki PLA, Luukkainen T. Levonorgestrel plasma concentrations and hormone profiles after insertion and after one year of treatment with a levonorgestrel-IUD. Contraception 1980, 21: 225-238.
67. Jia MC, Zhou LY, Ren S, Dong L, Xiao B. Serum SHBG levels during normal menstrual cycle and after insertion of levonorgestrel-releasing IUD Adv Contracept 1992; 8: 33-40.
68. Misra JS, Engineer AD, Randon T Cervical cytology associated with levonorgestrel contraception. Acta Cytol 1995; 39: 45-49.